Trial · NCT07152769
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
NCT07152769, Phase 2, Not yet recruiting, Fudan University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC. Trials, record NCT07152769. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07152769
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
- NCT number
- NCT07152769
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 104 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Advanced Intrahepatic Cholangiocarcinoma
- Interventions
- Iparomlimab and Tuvonralimab + GC, Sintilimab + GC
- First posted
- 2025-09-03
- Last updated
- 2025-09-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month progression-free survival | 6 months | Defined as the proportion of subjects who remain free of disease progression or death within 6 months from the start of the first study treatment. |
| Secondary | Progression-Free Survival (PFS) | up to approximately 2 years. | Defined as the time from randomization to the first documented radiological disease progression or death (whichever occurs first). |
| Secondary | Objective Response Rate (ORR) | up to approximately 2 years. | Defined as the proportion of subjects achieving a Complete Response (CR) or Partial Response (PR) among all subjects. |
| Secondary | Disease Control Rate (DCR) | up to approximately 2 years. | Defined as the proportion of subjects achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) among all subjects. |
| Secondary | Duration of Response (DOR) | up to approximately 2 years. | Defined as the time from the first documented response (CR or PR) to disease progression or death (whichever occurs first). |
| Secondary | Time to Response (TTR) | up to approximately 2 years. | Defined as the time from randomization to the first documented Complete Response (CR) or Partial Response (PR). |
| Secondary | Overall Survival (OS) | up to approximately 2 years. | Defined as the time from randomization to death from any cause. |
| Secondary | Adverse Events | up to approximately 2 years. | AE assessed by NCI-CTCAE v5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07152769
GET https://conductscience.org/api/trials/v1/NCT07152769/registered